Latest news with #JamesFerguson
The Herald Scotland
27-05-2025
- General
- The Herald Scotland
Fish stew earned The Palmerston chef high five from Richard E. Grant
The 60-cover restaurant is housed in a former 19th-century bank, and includes an in-house bakery that serves freshly baked bread and pastries This week, co-founder and chef Lloyd Morse answers our chef Q&A. What was your first kitchen job? I started washing up in a local restaurant outside Sydney when I was 15 Where is your favourite place to eat out? Kinneuchar Inn, Kilconquhar Fife. James Ferguson is one of the best chefs in the UK. What is your guilty pleasure meal? Buy a supermarket margarita pizza. Put ham and pineapple on it, then grate loads of Comté on it. Can you share a memory of your worst kitchen disaster? When I first moved to London, I worked at a now closed restaurant called Magdalen. After being there nearly a year I was promoted to sous chef, my first kitchen management position. We worked with whole animals mostly and on my first Saturday night running the kitchen myself I managed to overcook an entire 4-5kg beef rump. I can remember cutting into it and steam rising out of the grey meat. Still haunts my dreams. What is your signature dish? The menu at The Palmerston changes daily. Because of this we don't really have a signature dish, we relish the perpetuity of a changing menu! But one of the things we're known for is our pies for two to share. The fillings often change, but the lamb fat pastry is a constant! Who would you say is your biggest inspiration? I couldn't ever pin it on one person. There have been too many. Read more: What is one of your pet peeves as a chef? Spoons in pockets. Disgusting. If you weren't a chef, what do you think you would be doing with your life? I'd love to be able to work outdoors full time. Even in the horrendous Scottish winter. Pictured: Lloyd Morse, co-founder and chef at The Palmerston in Edinburgh (Image: Supplied) What's your favourite trick for making cooking at home easier? Learn to sharpen a knife. An accident with a blunt knife will hurt a lot more than a sharp one. And buy the best pots and pans you can. Wide and heavy-bottomed! What has been one highlight that stands out in your career so far? Being placed on the National Restaurant Award's top 100 restaurants before we'd been open for a year. It's voted by the industry itself, so it felt like a big welcome hug by hospitality. But also Richard E. Grant high-fiving me for a fish stew I cooked him.
The Sun
20-05-2025
- Entertainment
- The Sun
Horse racing tips: ‘He has a lovely draw under Hollie Doyle' – Templegate's 5-2 NAP the one to beat
TEMPLEGATE takes on Wednesday's racing looking for winners. Back a horse by clicking their odds below. DRAMA (8.10 Kempton, nap) He ran a career best when only just held in a competitive contest at Southwell last month. The handicapper has nudged him up a pound but that should not be a problem now back at a track he has won at twice in the past. He has a lovely draw in stall three which should allow Hollie Doyle to get him switched off early off and if he settles then he looks the one they all have to beat for in-form trainer James Ferguson. GETALEAD (5.25 Warwick, nb) Was a big eyecatcher when finishing strongly for third over shorter at Newton Abbot a week ago. A return to further will make him hard to beat. Should be hard to beat in this modest contest. First-time cheekpieces will help him focus and it would be disappointing if he does not progress through the handicap ranks. 2.00 Copper Knight 2.30 Underwriter 3.00 Henery Hawk 3.30 Commanding Prince (treble) 4.05 Hosanna Power 4.42 John L Sullivan 5.17 Beltane Brighton 6.00 Pop Dancer 6.30 Immediate Effect 7.00 Mr Ubiquitous 7.30 Devasboy 8.00 Versatile 8.30 Mashaan Chepstow 2.22 Ammes 2.52 Crackamour 3.22 Shaatir 3.55 Rosenpur 4.25 Art Of Fox 5.00 Marsh Benham 5.35 Vape Kempton 5.05 Brize Norton 5.40 Moderna 6.10 Opening Bat 6.40 Bill's Baar 7.10 Madame X 7.40 Racingbreaks Ryder 8.10 Drama (nap) 8.40 Aikhal Warwick 2.40 Roadshow 3.10 Rukaana 3.40 Pride Of Paris 4.15 Ukantango 4.50 A Dublin Job 5.25 Getalead (nb) Commercial content notice: Taking one of the offers featured in this article may result in a payment to The Sun. You should be aware brands pay fees to appear in the highest placements on the page. 18+. T&Cs apply. Remember to gamble responsibly A responsible gambler is someone who:
Business Wire
08-05-2025
- Business
- Business Wire
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
PONTE VEDRA, Fla.--(BUSINESS WIRE)-- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin. 'In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024,' said Quang X. Pham, Chairman & CEO. 'The appointment of James Ferguson, M.D., FACC, FAHA, as our Chief Medical Officer positions us for success in reviewing potential assets to add to our portfolio and designing and executing our clinical program for tecarfarin. The finalized Collaboration Agreement with Abbott validates the critical need in the market for a new anticoagulant for patients with left ventricular assist devices (LVADs). And our meeting with the FDA provided additional guidance in the design of a pivotal trial.' Highlights from the Quarter Ended March 31, 2025, and Other Recent Events: Leadership Advances In February 2025, Cadrenal appointed James J. Ferguson, M.D., FACC, FAHA, as Chief Medical Officer to lead the review of business development opportunities to expand the Company's pipeline and drive the late-stage clinical development of tecarfarin for conditions requiring chronic anticoagulation therapy. Regulatory Update In February 2025, Cadrenal met with the U.S. Food and Drug Administration (FDA) for a Type D meeting. The FDA provided additional guidance on the appropriate design for a Phase 3 tecarfarin trial and welcomed submission of a final study design for review. Collaboration Agreement with Abbott In March 2025, we announced a Collaboration Agreement with Abbott (NYSE: ABT) to support our pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. Under the agreement, Abbott will share insights from recent HeartMate 3™ clinical trials and will support Cadrenal with trial design, site identification, trial awareness, and HeartMate 3™ expertise. Operational Milestones During the quarter, Cadrenal successfully completed the technical transfer and manufacturing of its tecarfarin drug substance (API) from a CDMO site located in Asia to a CDMO site in the United States. This initiative was done to support the company's clinical and regulatory development strategy for tecarfarin and to improve supply chain security. Cadrenal also conducted strategic market opportunity research for multiple indications, including patients with left ventricular assist devices. This research indicates that tecarfarin is uniquely positioned to provide clinical value to patients in the rapidly growing LVAD market, which is projected to nearly double by 2032. This research also showed that tecarfarin has the potential to provide clinical benefit in additional high-need cardiovascular, renal, and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients. Participation in Key Investor, Medical, and Business Development Conferences Cadrenal was active during the first quarter in several significant conferences to build corporate visibility and underscore its commitment to advancing innovation in anticoagulation therapy. Investor interactions included participation at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, a Company presentation at the BIO CEO and Investor Conference in New York, and, after the close of the quarter, a Company presentation at the Centri Capital Conference at Nasdaq headquarters in New York. Shortly after the quarter's close, Cadrenal participated in the 18 th National Conference on Anticoagulation Therapy in Washington, D.C. Strategic Development Collaborations Cadrenal continues to explore opportunities to add to the Company's clinical pipeline and collaborate with potential development partners to advance the development of tecarfarin for patients with LVADs and for other indications requiring chronic anticoagulation. First Quarter 2025 Financial Highlights Research and development expenses for the quarter ended March 31, 2025, were $1.7 million compared to $0.6 million for the same period in 2024. General and administrative expenses for the quarter ended March 31, 2025, were $2.3 million compared to $1.1 million for the same period in 2024. Cadrenal reported a net loss of $3.8 million for the quarter ending March 31, 2025, compared to $1.7 million for the same period in 2024. On March 31, 2025, Cadrenal had cash and cash equivalents of $7.3 million, compared to $10.0 million as of December 31, 2024. The Company had approximately 1.9 million shares of common stock outstanding as of March 31, 2025. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal's lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for a number of indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin and capture value in a market with high demand for safer, more manageable treatment options. Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn. Safe Harbor Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potentially,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding the appointment of James Ferguson, M.D., FACC, FAHA, as the Company's Chief Medical Officer positioning the Company for success in reviewing potential assets to add to its portfolio and designing and executing its clinical program for tecarfarin; the finalized Collaboration Agreement with Abbott validating the critical need in the market for a new anticoagulant for patients with left ventricular assist devices (LVADs); Abbott sharing insights from recent HeartMate 3™ clinical trials and supporting Cadrenal with trial design, site identification, trial awareness, and HeartMate 3™ expertise; the LVAD market projected to nearly double by 2032; and tecarfarin having the potential to provide clinical benefit in additional high-need cardiovascular, renal, and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to utilize Abbott's expertise to advance tecarfarin, the ability to successfully collaborate with Abbott, the initiation of the pivotal clinical trial for tecarfarin in LVAD patients by Cadrenal; for tecarfarin to provide clinical benefit in additional high-need cardiovascular, renal, and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. (Tables to Follow) Cadrenal Therapeutics, Inc. Balance Sheets March 31, 2025 (unaudited) Assets: Current assets: Cash and cash equivalents $ 7,336,072 $ 10,017,942 Interest receivable 24,664 38,153 Prepaid expenses and other current assets 575,605 42,257 Deferred offering costs 8,451 14,445 Total current assets 7,944,792 10,112,797 Property, plant and equipment, net 4,678 6,944 Other assets 3,792 3,792 Total assets $ 7,953,262 $ 10,123,533 Liabilities and Stockholders' Equity: Current liabilities: Accounts payable $ 1,278,402 $ 1,502,468 Accrued liabilities 561,764 1,181,490 Total current liabilities 1,840,166 2,683,958 Total liabilities 1,840,166 2,683,958 Stockholders' equity: Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding at March 31, 2025 and December 31, 2024 - - Common stock, $0.001 par value; 75,000,000 shares authorized, 1,909,732 shares issued and outstanding as of March 31, 2025; 1,782,486 shares issued and outstanding as of December 31, 2024 1,909 1,782 Additional paid-in capital 35,679,350 33,160,576 Accumulated deficit (29,568,163 ) (25,722,783 ) Total stockholders' equity 6,113,096 7,439,575 Total liabilities and stockholders' equity $ 7,953,262 $ 10,123,533 Expand (1) All share and per share information has been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on August 20, 2024. Expand
Yahoo
03-04-2025
- Business
- Yahoo
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
Management Available for One-to-One Meetings PONTE VEDRA, Fla., April 03, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company's commitment to advancing innovation and clinical development in anticoagulation therapy. Chief Operating Officer, Jeff Cole and Chief Medical Officer, Dr. James Ferguson will represent the Company at the 18th National Conference on Anticoagulation Therapy in Washington, D.C. from April 3-5, engaging with leading experts and key opinion leaders in anticoagulation therapy. Additionally, Dr. Ferguson will attend the 13th annual CMO Summit 360° ® taking place on April 7-8, the largest gathering of biotech Chief Medical Officers across indications, modalities, company stages, professional experience levels, and geographic locations. Expanding its industry and business development engagement, the Company will be at the BIO International Convention, the world's largest biotechnology conference, from June 16-19, 2025 in Boston, MA, to meet with potential partners and collaborators to advance and enhance our lead program, tecarfarin and to build our pipeline in specialized cardiovascular therapeutics. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant to address unmet needs in anticoagulation therapy. Tecarfarin is a novel, and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. Although warfarin is widely used off-label for several rare cardiovascular conditions, extensive clinical and real-world data have shown it to have significant serious side effects. With tecarfarin, Cadrenal aims to meet the unmet needs of these patient populations by relieving them and their healthcare providers of some of warfarin's greatest clinical challenges. Cadrenal is pursuing a product-in-a-pipeline approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus to build a pipeline of specialized cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn. View source version on Contacts Corporate and Investor Relations Lisa DeScenzaLaVoieHealthScience(978) 395-5970ldescenza@ Media Andrew KordaLaVoieHealthScience(617) 865-0043akorda@ Sign in to access your portfolio
